Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-398-6
CAS number: 106-44-5
600 mg/kg: 3 females died within the first 3 days of dosing.
Overt signs of toxicity at this dose included lethargy, tremors, convulsions and coma.
BODY WEIGHT was sign. reduced (p</=0.05): 50 mg/kg bw: female, at week 1, 2, 3, 4, 5, and 7 175 mg/kg bw: male, at week 2, 3, and 4 600 mg/kg bw: male, except week 1 in all weeks; female, week 2, 3, 4, 5, 6, 7, 8, 9, and 14 BODY WEIGHT GAIN was sign. reduced (p</=0.05): 50 mg/kg bw: female, week 2, and 3 175 mg/kg bw: male, week 1, 2, and 3; female, week 1 and 2 600 mg/kg bw: male, all weeks; female, week 1, 2, 3, 4, 5, 6, 7, 10, 13 FOOD CONSUMPTION data was sign. reduced (p</=0.05): 50 mg/kg bw: male, week 5, 9; female, week 1 and 2 175 mg/kg bw: male, week 1, and 5 600 mg/kg bw: male, week 1, 2, 3, 4, 5, 6, 7, and 9; female, week1, 2, and 5 CLINICAL PATHOLOGY, only sign. changes (p</=0.05): Male: APTT, 600 mg/kg bw, increased; total protein from 175 mg/kg bw increased; Ca, at 175 mg/kg bw increased; phosphate, 600 mg/kg bw, increased Female: RBC, HGB, HCT, from 175 mg/kg bw, decreased; CO2, at 175 mg/kg bw, decreased; SGPT, SGOT, Cholesterin, at 600 mg/kg bw increased; OPHTHALMOLOGY: Treatment related changes were not seen. ORGAN WEIGHTS (rel. and abs., only sign. changes, p</=0.05): Male: Heart, rel., at 600 mg/kg bw increased; liver, 600 mg/kg bw, abs. decrease, rel. increase; spleen, 600 mg/kg bw, absol. decreases; right and left kidney, from 175 mg/kg bw, rel. increased; right and left testis, at 600 mg/kg bw, rel. increased; brain, at 600 mg/kg bw, abs. decreased, rel. increased; Female: spleen, at 50 mg/kg bw, rel. increased (no histopathologic correlate); right kidney, at 600 mg/kg bw, rel. increased; right ovary, at 600 mg/kg bw, ovary and brain, abs. decreased PATHOLOGY: Gross necropsy examinations did not detect treatment- related changes. Histological examination: male: chronic nephropathy in all rats including controls: a slight increased incidence in all dosed males when compared to the controls. The increased incidence was significantly greater (p</=0.05) at the low and the high dose but not at the middle dose. The proportion of rats with minimal and mild nephropathy was generally similar for all male rats including controls: controls: 4/20 = 20%, severity(s): minimal 3/4, mild 1/4; 50 mg-gr.: 11/20 = 55%, s: minimal: 3/11, mild: 2/11 175 mg-gr.: 7/20 = 35%, s: minimal: 7/7, mild:0/7 600 mg-gr.: 12/20 = 60%, s: minimal: 9/12, mild: 3/12 (no dose-response relationship, controls also affected, no increase in percentage of severity in dosed rats when compared to the controls) male, female: epithelial metaplasia of the trachea: sign, at 600 mg/kg bw (p</=0.05), 10/20 males, 9/19 females The incidence of this lesions was similiar for low dose, mid dose and control.
In a subchronic toxicity study according to OECD TG 408 p-cresol was administered daily to male and female Sprague-Dawley rats by gavage at dose levels of 0, 50, 175 , 600 mg/kg bw/day diluted in corn oil. Based on increased mortality, clinical signs including lethargy, exessive salivation, tremor and occasional convulsions and comas, hepatotoxicity and nephrotoxicity from 175 mg/kg bw/d onwards. The NOAEL is 50 mg/kg bw/d (RTI 1988).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Siekdami užtikrinti, kad būtų patogu naudotis mūsų svetaine, jos tinklapiuose naudojame slapukus.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again